Literature DB >> 23724525

The efficacy of intrauterine versus oral progestin for the treatment of endometrial hyperplasia. A prospective randomized comparative study.

K Dolapcioglu1, A Boz, A Baloglu.   

Abstract

OBJECTIVES: This study compared the efficacy of the levonorgestrel-releasing intrauterine device (LNG-IUD) to oral medroxyprogesterone acetate (MPA) applied for the same length of time for the management of endometrial hyperplasia without atypia. STUDY
DESIGN: This was single-center, open, randomized, and clinical trial. One hundred four patients aged between 30-50 years and diagnosed with endometrial hyperplasia without atypia by endometrial biopsy, were randomized to receive LNG-IUD or MPA. Both groups were further divided into two groups as three-month and six-month treatment subgroups. The primary objective was to compare the complete regression rates of hyperplasia, and the secondary objective was to determine the minimum duration of time required for the achievement of regression.
RESULTS: At two-year follow-up, the success rates of LNG-IUD treatment and oral MPA for three months therapy were 84% and 50%, respectively. While the regression rate was 100% in the six-month LNG-IUD group, it was 64% in the oral MPA group. LNG-IUD appeared to have a significantly higher success rate (p = 0.0001).
CONCLUSION: It is believed that by this study LNG-IUD applications may be a reliable preference for younger patients who wish to preserve their uterus and especially for non-atypical cases, and if the patient demands fertility, even a six-month application will provide effective treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23724525

Source DB:  PubMed          Journal:  Clin Exp Obstet Gynecol        ISSN: 0390-6663            Impact factor:   0.146


  7 in total

Review 1.  Current Issues in the Diagnosis and Treatment of Endometrial Carcinoma.

Authors:  J Stubert; B Gerber
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-02       Impact factor: 2.915

2.  Progestin therapy for obese women with complex atypical hyperplasia: levonorgestrel-releasing intrauterine device vs systemic therapy.

Authors:  Rachel S Mandelbaum; Marcia A Ciccone; David J Nusbaum; Mahdi Khoshchehreh; Heena Purswani; Elise B Morocco; Meghan B Smith; Shinya Matsuzaki; Christina E Dancz; Begum Ozel; Lynda D Roman; Richard J Paulson; Koji Matsuo
Journal:  Am J Obstet Gynecol       Date:  2020-01-21       Impact factor: 8.661

3.  Levonorgestrel-releasing intrauterine system for endometrial hyperplasia.

Authors:  Theresa Mittermeier; Charlotte Farrant; Michelle R Wise
Journal:  Cochrane Database Syst Rev       Date:  2020-09-06

4.  Role of the levonorgestrel intrauterine system in effective contraception.

Authors:  Abdelhamid M Attia; Magdy M Ibrahim; Ahmed M Abou-Setta
Journal:  Patient Prefer Adherence       Date:  2013-08-09       Impact factor: 2.711

Review 5.  Comparison among fertility-sparing therapies for well differentiated early-stage endometrial carcinoma and complex atypical hyperplasia.

Authors:  Qing Zhang; Gonghua Qi; Margaux J Kanis; Ruifen Dong; Baoxia Cui; Xingsheng Yang; Beihua Kong
Journal:  Oncotarget       Date:  2017-05-03

Review 6.  Endometrial hyperplasia as a risk factor of endometrial cancer.

Authors:  Lisa K Nees; Sabine Heublein; Sahra Steinmacher; Ingolf Juhasz-Böss; Sara Brucker; Clemens B Tempfer; Markus Wallwiener
Journal:  Arch Gynecol Obstet       Date:  2022-01-10       Impact factor: 2.493

7.  Comparison of diagnostic accuracy between endometrial curettage and aspiration biopsy in patients treated with progestin for endometrial hyperplasia: a Korean Gynecologic Oncology Group study.

Authors:  Mi Kyoung Kim; Seok Ju Seong; Dong Choon Park; Jin Hwa Hong; Ju Won Roh; Soon Beom Kang
Journal:  J Gynecol Oncol       Date:  2020-02-07       Impact factor: 4.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.